This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This is a pilot phase I study of decaffeinated green tea concentrate combined with Capsicum vanilloid and available commercially as a nutriceutical, Capsibiol-T. It will be done in four patients with either metastatic melanoma or metastatic renal cell cancer. The purpose is to obtain pilot clinical and pharmacokinetic data in human cancer patients with the commercially recommended (or slightly higher than recommended) dose. Blood levels of the the presumptive active ingredients of green tea will be measured asa well as levels of VEGF and NO. It is hoped that this pilot data will serve as a basis for a future grant application.
Showing the most recent 10 out of 767 publications